Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 99   

Articles published

CBST 67.34 +1.45 (2.20%)
price chart
Cubist Pharma CEO Bonney will step down Dec. 31
Cubist Pharmaceuticals Inc. is based in Lexington, Massachusetts. Its primary product is Cubicin, which is used to treat infections of the skin and blood.
Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer  MarketWatch
New Cubist Pharmaceuticals chief executive will be Robert J. Perez  Boston Globe
Related articles »  
News Round Up- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cubist ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) recently declared that the U.S. Food and Drug Administration have granted Breakthrough Therapy designation to NUPLAZID for the treatment of Parkinson's disease psychosis.
Related articles »  
Stocks Alert: Energy XXI (Bermuda) Limited (NASDAQ:EXXI), Ohr ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) said its president and chief operating officer Robert J. Perez will take over as Chief Executive Officer, effective January 1, 2015, replacing Michael Bonney who is retiring.
Related articles »  
Cubist Pharma Names COO Robert Perez CEO
Cubist Pharmaceuticals, Inc. (CBST: Quote) Monday said it appointed Chief Operating Officer and President Robert Perez as its CEO, with effect from January 1, 2015, to replace Michael Bonney who will be retiring by the year end.
Traders Recap -Cubist Pharmaceuticals Inc (NASDAQ:CBST), Crown Holdings ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) will issue its third quarter 2014 financial results at 4:00 p.m. ET on Tuesday, October 21, 2014.
Cubist Pharmaceuticals (CBST) to Release Earnings on Tuesday
Cubist Pharmaceuticals has a 1-year low of $58.50 and a 1-year high of $82.12. The stock has a 50-day moving average of $66.07 and a 200-day moving average of $66.58.
Cubist CEO Bonney Will Step Down Dec. 31
Cubist Pharmaceuticals Inc. is based in Lexington, Massachusetts. Its primary product is Cubicin, which is used to treat infections of the skin and blood.
Cubist Pharmaceuticals EVP Unloads $3146894 in Stock (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) EVP Steven C. Gilman sold 48,125 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $65.39, for a total ...
Related articles »  
Morningstar Assigns BBB- Credit Rating to Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has received a �BBB-� credit rating from analysts at Morningstar.
News Buzz: Zynga Inc (NASDAQ:ZNGA), Cubist Pharmaceuticals Inc. (NASDAQ ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) announced that it will present new data from its antibiotics portfolio at IDWeek 2014, October 8-12, in Philadelphia, PA.